Residalya acquired by Domusvi

FRANCE Health Providers / Healthcare Facilities / Nursing Homes EV €100–350M

Context

DomusVi entered into exclusive negotiations to acquire 100% of the capital of Residalya, in a move designed to significantly densify its territorial coverage within France. The transaction allowed DomusVi to absorb 35 additional facilities and roughly 2,630 beds, bringing its total capacity to over 17,000 beds and narrowing the gap with its primary market competitors. This strategic build-up was motivated by the need to reach a critical industrial scale, merging Residalya’s localized expertise and specialized assets—including the ownership of twelve of its residences—into DomusVi’s global operational platform.

Residalya, which reported an EBITDA margin of [members only] in 2016, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x in 2026).

-> Deep-dive in Healthcare & Pharma market trends

Target

Residalya functions as a significant operator in the French elderly care market, managing a nationwide network of 35 facilities that include both medicalized nursing homes and autonomous senior residences. Prior to its acquisition, the company controlled approximately 2,630 beds and maintained a strong regional presence, particularly in the Nouvelle-Aquitaine and Provence-Alpes-Côte d'Azur regions.

Ent. Value

€100–350M

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2016

2015

Other operations with Domusvi

Other operations with Domusvi
Date	Acquirer	Target	Country	Sector
04/2021	ICG / MANAGEMENT & PRIVATE INVESTORS	DOMUSVI	FRANCE	Nursing Homes
06/2017	ICG / MANAGEMENT & PRIVATE INVESTORS	DOMUSVI	FRANCE	Nursing Homes
10/2016	DOMUSVI	SARQUAVITAE	SPAIN	Nursing Homes
06/2014	PAI PARTNERS	DOMUSVI	FRANCE	Nursing Homes

Similar deals in Health Providers

Similar deals in Health Providers
Date	Acquirer	Target	Country	Sector
07/2019	TRITON PARTNERS	ALERIS	SWEDEN	Clinics / Hospitals
04/2019	COLISÉE	ARMONEA	BELGIUM	Nursing Homes
01/2019	HUMANA	CORONARIA HOIVA	FINLAND	Nursing Homes
11/2018	DENTALPRO	CLINIODENT	SWITZERLAND	Dental Centers
04/2018	INVESTINDUSTRIAL	LIFEBRAIN	ITALY	Labs (Biology)
03/2018	THE ADOLFSEN GROUP	FRÖSUNDA	SWEDEN	Healthcare Facilities
03/2018	ICV PARTNERS	OUTPATIENT IMAGING AFFILIATES	UNITED STATES	Radiology
01/2018	PERMIRA	I-MED RADIOLOGY NETWORK	AUSTRALIA	Radiology
06/2017	ICG / MANAGEMENT & PRIVATE INVESTORS	DOMUSVI	FRANCE	Nursing Homes
05/2017	BC PARTNERS	DENTALPRO	ITALY	Dental Centers

REFERENCES

Valuation range: EV €100–350M

Revenue range: €100–200M

EV/Revenue range: 1x - 3x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Residalya by Domusvi are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: residalya

FAQ

What transaction does this page cover?

This page covers Domusvi’s acquisition of 100% of Residalya, a French company specialised in Healthcare Facilities, in 2019.

How was the acquisition of Residalya by Domusvi valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €100–350M band and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What was Residalya’s revenue at the time of the deal?

At the time of the transaction, Residalya’s annual revenue was estimated within the €100–200M range (FY 2016). Detailed financial figures are available to members.

How does the valuation of Residalya compare to benchmarks in the Healthcare & Pharma sector?

Transaction multiples for this specific deal are exclusively reserved for mynth members. By way of comparison, in 2026 companies in the Healthcare & Pharma sector are valued at a multiple of 14.3x EBITDA.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.